CRISPR Therapeutics AG is rated a Buy with $1.9B cash, prudent management, and undervalued shares. Learn more about CRSP ...

The discovery of the DNA structure sparked a flurry of new research, birthing fields like molecular biology, biotechnology, ...

A major medical milestone took place in May 2025, when doctors at the Children’s Hospital of Philadelphia used CRISPR-based ...

Thinking about CRISPR Therapeutics and wondering if now is your chance to scoop up value, or if the stock is already priced in with the excitement? Let's break down what the numbers and news say about ...

An experimental gene-editing therapy developed by Crispr Therapeutics is showing promise for treating heart disease.

From revolutionary CRISPR treatment to heavy drinking dangers, here's what you need to know about the latest health research.

Scientists at St. Jude Children's Research Hospital and Northwestern University identified a previously unknown treatment ...

Sohini Ramachandran is a professor of biology, data science, and computer science at Brown University. C. Brandon Ogbunu is ...

Ecuadorian scientists are developing a biotechnological strategy to stop banana wilt by genetically editing the causative ...

Using the CRISPR-Cas9 tool, the researchers edited the toad eggs to turn off a gene known as tyrosinase, which is responsible ...

Dyadic International Inc (DYAI) marks a pivotal shift towards commercialization with strategic partnerships and technological advancements, despite facing revenue and net loss hurdles.

Pioneering CRISPR trial shows single infusion permanently lowers bad cholesterol by 50% in patients who don't respond to medication.